Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Importance: Predicting undesirable outcomes following anti-VEGF initiation in macular oedema is critical for effective clinical decision-making and optimised care. Objective: To estimate the time to undesirable events in diabetic macular oedema (DMO), central and branch vein occlusions (CRVO and BRVO) after appropriate loading doses with either ranibizumab or aflibercept and identified baseline predictors of negative outcome. Design, setting, participants: A retrospective cohort study of 3277 patients ( N = 2107 in DMO, N = 413 in CRVO and N = 757 in BRVO) collected over a 10-year period, in a large UK tertiary centre. Only one eye was included per patient. Inclusion criteria pre-specified a minimum of two clinic visits with one being at least 6 months post treatment. Main outcome and measures: The main outcome measure was absence of visual acuity (VA) improvement due to macular oedema failure of anti-VEGF therapy (defined as VA gain <5 ETDRS letters and CST increase of 50 µm or CST > 325 µm) modelled using time-event analyzes of appropriately loaded patients. Secondary outcomes included survival curves by individual condition (DMO, CRVO, BRVO) and factors associated with negative outcomes. Results: After starting anti-VEGF , there was a 50% chance of undesirable outcomes at 2.3, 5.24 and 6.16 years for DMO, CRVO and BRVO, respectively. Cox proportional hazards modelling identified presenting age, intraretinal (IRF) volume, presence of DMO and VA as predictors of negative outcomes, whilst South East Asian ethnicity conferred an independent protective effect. Conclusion: Real-world data suggest that undesirable events following anti-VEGF injections is likely to in 50% of patients by the third year of treatment in spite of appropriate loading. The definition of undesirable treatment events captured nearly all patients who were escalated to another therapy, but this proportion represented a small percentage of our definition of failed response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, anti-VEGF injections failed to improve or stabilise visual outcomes in over 50% of DMO patients after two years of treatment [73].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 1×
“Macular fluid accumulates in diabetic eye disease (diabetic macular oedema [DMO]) and retinal vein occlusions (RVO) that includes both central retinal vein occlusion (CRVO) and branch retinal vein occlusions (BRVO)—the three common retinal vascular diseases that cause visual impairment [1, 2].”
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,155
Rogers, S., McIntosh, R. L., Cheung, N., Lim, L., Wang, J. J., Mitchell, P., Kowalski, J. W., Nguyen, H., & Wong, T. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.07.017 · Cited by 1,145
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.022 · Cited by 1,051
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 573
Gross, J. G., Glassman, A. R., Liu, D., Sun, J. K., Antoszyk, A. N., Baker, C. W., Bressler, N. M., Elman, M. J., Ferris, F. L., Gardner, T. W., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3255 · Cited by 404
Cited by
Age-related macular degeneration in 2025- opportunities and challenges
Cheung, C. M. G. (2025) · Eye · doi:10.1038/s41433-025-03710-8 · Cited by 5
Wang, E., Feng, B., Chen, S., Wang, H., Ling, T., & Chakrabarti, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.1.24 · Cited by 2
Ziemssen, F., Loewenstein, A., & Aslam, T. M. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.02.007 · Cited by 2
Gao, L., Cai, X., & Dang, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s604539 · Cited by 1
Li, J. (2026) · American Journal of Translational Research · doi:10.62347/ryms1737 · Cited by 1
Metadata
- Authors
- Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- National University of Singapore (SG)
- Roche (United States) (US)
- Corresponding author
- Fu, Dun Jack
- ORCID
- Venue
- Eye
- Published
- 2024-12-10
- Volume
- 39
- Issue
- 5
- Pages
- 977-985
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC11933433
- OpenAlex
- W4405225188
- Cited by
- 14
- References
- 34
- Citations by year
- 2026: 11 · 2025: 3
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Eye (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- AbbVie (SIMD1004)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- anti-VEGF therapy, treatment failure, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, ranibizumab, aflibercept, visual acuity loss, macular thickness, predictors of treatment failure, real-world outcomes
- MeSH terms
- Ranibizumab, Aged, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Recombinant Fusion Proteins, Retinal Vein Occlusion, Retrospective Studies, Visual Acuity, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. https://app.cochat.ai/papers/10.1038/s41433-024-03529-9
- The paper
- Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025). Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. Eye. https://doi.org/10.1038/s41433-024-03529-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.